Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: smh who wrote (2500)	1/18/2001 12:51:40 PM
From: nigel bates	Read Replies (1) of 52153

Revised "Cross" portfolio Pretty decent performance over 18 days (g). MCDE gave the Iconix holding as 29% in the H& Q presentation, FWIW. Another candidate below ? Jan 18 (Reuters) - Biotechnology firm ML Laboratories Plc (MLB.L) said on Thursday it delayed the flotation of its respiratory drugs unit Innovata Biomed while it undertakes a strategic review... The company expressed concern about its share price and said it had brought in NM Rothschild for the review. As a result, the planned Nasdaq flotation of Innovata, which makes inhalers for asthma and other drugs, was put on hold. Analyst estimates last January valued Innovata in a range between $100-$500 million, but the upper end of the range appears far too high when compared with the current 165 million pound ($243 million) market valuation for all of ML Labs.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next